Curevac has been granted a patent for a vaccine utilizing mRNA to elicit immune responses in elderly patients, particularly against influenza. The method involves administering RNA molecules encoding antigens from multiple influenza strains, enhancing T cell-mediated immunity compared to traditional inactivated vaccines. GlobalData’s report on Curevac gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Curevac, Personalized cancer vaccines was a key innovation area identified from patents. Curevac's grant share as of June 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Mrna vaccines for stimulating immune response in elderly patients
The patent US12036277B2 outlines a method for stimulating a protective immune response against influenza in patients through the administration of a composition containing at least two RNA molecules. These RNA molecules encode influenza haemagglutinin (HA) antigens derived from at least three different strains of influenza. Notably, the RNA exhibits an elevated G/C content in the coding sequence compared to wild-type RNA, which is designed to enhance the T cell-mediated immune response, specifically a CD8+ T cell response, when compared to traditional inactivated influenza vaccines. The method allows for the administration of the composition via intradermal or intramuscular injection.
Additionally, the claims detail the potential inclusion of other influenza antigens, such as neuraminidase, matrix protein, or nucleoprotein, alongside the HA antigens. The RNA molecules may also feature modifications, such as nucleotide analogs or structural enhancements like a 5' cap and poly-A tail, to improve their efficacy. The patent specifies that the HA antigens can be from various subtypes, including H1, H3, and others, and emphasizes the possibility of using lipid particles or other agents to enhance the transfection efficiency of the RNA molecules. The method may involve multiple administrations to further bolster the immune response, highlighting a comprehensive approach to influenza vaccination through innovative RNA technology.
To know more about GlobalData’s detailed insights on Curevac, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
